Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last821 to 840 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Intervention Arm vs Placebo Arm: Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks) | 189 of 5,780 230 of 5,764 | -0.7 points -1.4 to -0.0 | 11,544 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Intervention Arm vs Placebo Arm: Incidence of Perinatal Mortality | 264 of 5,779 309 of 5,763 | -0.8 points -1.6 to -0.0 | 11,542 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Intervention Arm vs Placebo Arm: Maternal Outcome 2 - Incidence of Antepartum Hemorrhage | 26 of 5,761 25 of 5,746 | 0.0 points -0.2 to 0.3 | 11,507 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Benazepril / Amlodipine vs Benazepril / HCTZ: serious adverse events | 1,844 of 5,740 2,026 of 5,757 | -3.1 points -4.8 to -1.3 | 11,497 | NCT00170950 Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension |
| D-QIV vs Control: Number of Subjects With First Occurrence of Culture-confirmed Moderate to Severe Influenza A and/or B Disease Due to Antigenically-matching Influenza Strains. | 20 of 5,707 88 of 5,697 | -1.2 points -1.6 to -0.8 | 11,404 | NCT01439360 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children |
| D-QIV vs Control: Number of Subjects With First Occurrence of Culture-confirmed Moderate to Severe Influenza A and/or B Disease Due to Any Seasonal Influenza Strain. | 79 of 5,707 216 of 5,697 | -2.4 points -3.0 to -1.8 | 11,404 | NCT01439360 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children |
| D-QIV vs Control: Number of Subjects With First Occurrence of RT-PCR Confirmed Severe Influenza A and/or B Due to Any Seasonal Influenza Strain. | 2 of 5,707 3 of 5,697 | -0.0 points -0.1 to 0.1 | 11,404 | NCT01439360 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children |
| D-QIV vs Control: Number of Subjects With RT-PCR Confirmed Influenza of Any Severity. | 344 of 5,707 662 of 5,697 | -5.6 points -6.6 to -4.6 | 11,404 | NCT01439360 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children |
| D-QIV vs Control: Number of Subjects With First Occurrence of Culture-confirmed Influenza A and/or B Disease of Any Severity Due to Antigenically-matching Influenza Strains | 88 of 5,707 216 of 5,697 | -2.2 points -2.9 to -1.7 | 11,404 | NCT01439360 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children |
| D-QIV vs Control: Number of Subjects With First Occurrence of Acute Otitis Media (AOM) With RT-PCR Confirmed Influenza A and/or B Infection Due to Any Seasonal Influenza Strain. | 12 of 5,707 28 of 5,697 | -0.3 points -0.5 to -0.1 | 11,404 | NCT01439360 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children |
| D-QIV vs Control: Number of Subjects With First Occurrence of Culture-confirmed Influenza A and/or B Disease of Any Severity Due to Any Seasonal Influenza Strain. | 303 of 5,707 602 of 5,697 | -5.3 points -6.3 to -4.3 | 11,404 | NCT01439360 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children |
| D-QIV vs Control: Number of Subjects With Moderate to Severe RT-PCR Confirmed Influenza. | 90 of 5,707 242 of 5,697 | -2.7 points -3.3 to -2.1 | 11,404 | NCT01439360 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children |
| D-QIV vs Control: Number of Subjects With First Occurrence of Lower Respiratory Illness (LRI) With RT-PCR Confirmed Influenza. | 28 of 5,707 61 of 5,697 | -0.6 points -0.9 to -0.3 | 11,404 | NCT01439360 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children |
| Intervention Arm vs Placebo Arm: Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g | 78 of 5,628 101 of 5,624 | -0.4 points -0.9 to 0.1 | 11,252 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Intervention Arm vs Placebo Arm: Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g | 1,078 of 5,628 1,153 of 5,624 | -1.3 points -2.8 to 0.1 | 11,252 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Cardiovascular Disorders Digital Intervention Arm (CVD-I) vs Cardiovascular Disorders Without Digital Intervention Arm: Number of Participants With Self-reported Influenza Vaccination Status as Vaccinated | 3,418 of 5,575 3,355 of 5,662 | 2.1 points 0.2 to 3.9 | 11,237 | NCT04584645 A Digital Flu Intervention for People With Cardiovascular Conditions |
| Receives OUD-CDS vs Does Not Receive the OUD-CDS: deaths from any cause | 270 of 5,688 268 of 5,509 | -0.1 points -0.9 to 0.7 | 11,197 | NCT04198428 Clinical Decision Support for Opioid Use Disorders in Medical Settings (COMPUTE 2.0) |
| Receives OUD-CDS vs Does Not Receive the OUD-CDS: serious adverse events | 3,740 of 5,688 3,752 of 5,509 | -2.4 points -4.1 to -0.6 | 11,197 | NCT04198428 Clinical Decision Support for Opioid Use Disorders in Medical Settings (COMPUTE 2.0) |
| Open Group vs Masked Group: Number of Infants With Apgar Score < = 3 at 5 Minutes (Primary Outcome Component) | 17 of 5,532 6 of 5,576 | 0.2 points 0.0 to 0.4 | 11,108 | NCT01131260 Fetal ST Segment and T Wave Analysis in Labor |
| Open Group vs Masked Group: Number of Infants Experiencing Neonatal Encephalopathy (Primary Outcome Component) | 4 of 5,532 5 of 5,576 | -0.0 points -0.1 to 0.1 | 11,108 | NCT01131260 Fetal ST Segment and T Wave Analysis in Labor |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=42
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02409680-a525f01e",
"title": "Intervention Arm vs Placebo Arm: Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)",
"summary": "189 of 5780 against 230 of 5764; risk difference -0.7 points, 95% interval -1.4 to -0.0; NCT02409680, Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)",
"record": "/library/comparisons/NCT02409680-a525f01e",
"nct_id": "NCT02409680",
"kind": "outcome",
"participants": 11544,
"risk_difference": {
"value": -0.007203883308640434,
"lower": -0.01407070269491475,
"upper": -0.000373542906154432
},
"group_1": "189 of 5,780",
"group_2": "230 of 5,764",
"difference": "-0.7 points",
"interval": "-1.4 to -0.0",
"trial_title": "Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)"
},
{
"id": "NCT02409680-db11942d",
"title": "Intervention Arm vs Placebo Arm: Incidence of Perinatal Mortality",
"summary": "264 of 5779 against 309 of 5763; risk difference -0.8 points, 95% interval -1.6 to -0.0; NCT02409680, Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)",
"record": "/library/comparisons/NCT02409680-db11942d",
"nct_id": "NCT02409680",
"kind": "outcome",
"participants": 11542,
"risk_difference": {
"value": -0.007935263283862057,
"lower": -0.015893222638065328,
"upper": -0.000003573639746051044
},
"group_1": "264 of 5,779",
"group_2": "309 of 5,763",
"difference": "-0.8 points",
"interval": "-1.6 to -0.0",
"trial_title": "Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=43",
"request_id": "DfAHkDbCfNuHBLpH"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant